Scott Smith

Scott Smith leads Viatris as CEO, overseeing the global pharmaceutical company formed from the 2020 merger of generic drug maker Mylan and Pfizer's Upjohn division (which housed legacy brands like Lipitor, Norvasc, and Lyrica that had lost patent exclusivity). Viatris sells over 1,400 products in more than 165 countries, making it one of the most geographically diversified pharmaceutical companies. Viatris has been executing a strategic transformation: divesting non-core assets, using proceeds to reduce debt, and investing in a new product pipeline including biosimilars and novel medicines. The company has launched or is developing biosimilars for several major biologics, and has acquired branded assets to build a specialty pharmaceutical portfolio. The generic pharmaceutical industry faces structural headwinds from ongoing price erosion, but Viatris's global scale and diversified portfolio provide relative stability. Key stock drivers include revenue trajectory (managing base business erosion versus new product launches), biosimilar launch execution and market share, debt reduction progress, new product pipeline catalysts, generic drug pricing trends, geographic diversification benefits, operational restructuring and margin improvement, and dividend sustainability.